Sandra Robrecht
Overview
Explore the profile of Sandra Robrecht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, et al.
Blood
. 2025 Jan;
PMID: 39883943
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total,...
2.
Langerbeins P, Robrecht S, Nieper P, Cramer P, Furstenau M, Al-Sawaf O, et al.
J Clin Oncol
. 2024 Nov;
43(4):392-402.
PMID: 39602678
Purpose: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. Methods: The German CLL Study Group conducted a randomized, double-blind,...
3.
Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Furstenau M, et al.
J Clin Oncol
. 2024 Aug;
43(4):381-391.
PMID: 39213466
Purpose: Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level analysis describes the correlation between progression-free survival...
4.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang Y, Fink A, et al.
Blood
. 2024 Jul;
144(18):1924-1935.
PMID: 39082668
In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n ...
5.
Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl M, et al.
Hemasphere
. 2024 Jul;
8(7):e126.
PMID: 39050548
No abstract available.
6.
Furstenau M, Kater A, Robrecht S, von Tresckow J, Zhang C, Gregor M, et al.
Lancet Oncol
. 2024 May;
25(6):744-759.
PMID: 38821083
Background: In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates and progression-free survival compared with chemoimmunotherapy in...
7.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, et al.
Am J Hematol
. 2024 May;
99(8):1620-1623.
PMID: 38757754
No abstract available.
8.
Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuss A, et al.
Eur J Haematol
. 2024 May;
113(2):235-241.
PMID: 38693677
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term...
9.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, et al.
Blood
. 2024 Apr;
143(25):2588-2598.
PMID: 38620092
We evaluated the chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) in patients with CLL treated first line with targeted drugs (n = 991) or chemoimmunotherapy (n = 1256). With a...
10.
Furstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, et al.
Blood
. 2024 Apr;
144(3):272-282.
PMID: 38620072
The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)-guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia...